Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the ...

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...

Novo Nordisk's weight loss drug Wegovy will be available in France from Tuesday. The drug will require a prescription and ...

Novo Nordisk CEO Lars Fruergaard Jorgensen has called attention to the complexities of the U.S. healthcare system while ...

We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to ...

“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic ...

Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding ...